ArticleFrontiers in oncology2026
A multicenter, clinically interpretable prediction model for malignancy risk in C-TIRADS 3-4 thyroid nodules.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To develop and validate clinically interpretable prediction models that integrate ultrasonographic features and laboratory indicators for malignancy risk assessment in thyroid nodules, and to evaluate their potential value in supporting clinical decision-making. Methods: This was a multicenter retrospective study. 631 thyroid nodules from 478 patients at Yueyang People's Hospital and 193 thyroid nodules from 144 patients at Hunan Cancer Hospital were included. Data from Yueyang People's Hospital was used as the modeling cohort, randomly divided into a training set and an internal validation set (approximately 7:3) based on patient data. Data from Hunan Cancer Hospital served as an independent external validation set. Logistic regression, random forest, support vector machine(SVM), XGBoost, and LightGBM models were constructed based on ultrasound imaging features and clinical laboratory indicators, and their predictive performance was evaluated in the internal and external validation sets. Results: In the internal validation cohort, the logistic regression model achieved an area under the receiver operating characteristic curve (AUC) of 0.924 (95% CI: 0.881-0.959), comparable to the support vector machine (AUC = 0.922) and other machine learning models. In the external validation cohort, the AUCs ranged from 0.871 to 0.929, with logistic regression demonstrating strong and stable discriminative performance (AUC = 0.929, 95% CI: 0.887-0.965). Pairwise comparisons using the DeLong test showed that no statistically significant differences were observed between models in the internal validation cohort after Bonferroni correction. In contrast, in the external validation cohort, logistic regression demonstrated significantly higher AUCs than support vector machine, random forest, XGBoost, and LightGBM after correction. The logistic regression model also demonstrated balanced classification performance, good calibration, and favorable clinical utility in decision curve analysis. A nomogram was constructed based on this model for individualized malignancy risk assessment. Conclusions: This study demonstrates that, under strict variable selection, a logistic regression model based on routine clinical and ultrasound information can provide a stable and clinically interpretable risk assessment tool for C-TIRADS 3-4 thyroid nodules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.